BACKGROUND: Vyzulta (latanoprostene bunod; LB) is a topical prostaglandin analog for intraocular pressure (IOP) reduction in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This study assessed real-world LB use in patients with OAG or OHT.

METHODS: This retrospective, multicenter, cross-sectional case review and survey study included licensed ophthalmologists/optometrists (eye care practitioners; ECPs) with ≥3 years’ experience who prescribed on-label LB in ≥10 patients in the prior year. ECPs submitted deidentified cases via a case report form (CRF) and completed a retrospective survey. Outcomes included IOP, number of IOP-lowering medications, safety, utilization patterns, and ECP satisfaction.

RESULTS: This analysis included CRFs for 83 eyes of 55 patients across five US sites. Mean±standard deviation (SD) age was 68±15 years, and 56% were female; 70% (n=38/54; unknown, n=1) had ocular comorbidities. At baseline, mean±SD IOP (n=81 eyes) was 19.9±6.6 mmHg, with a mean±SD target IOP (n=76 eyes) of 14.6±2.4 mmHg. Median (interquartile range [IQR]) number of IOP-lowering medications (n=55 patients) was 1 (1–2). At most recent follow-up, 87% (n=48/55) of patients remained on LB, with a median (IQR) of 29 (17–52) weeks since treatment initiation. Mean±SD IOP (n=82 eyes) decreased by 32% to 13.5±3.8 mmHg; median (IQR) number of IOP-lowering medications (n=54 patients) was 1 (1–2). Of eleven adverse events in nine patients, decreased visual acuity was the most common. Five ECPs from five US practices completed the survey; all had ≥11 years’ experience and were mostly from medium-sized practices (11–50 ECPs). On average, ECPs prescribed LB as monotherapy in 184 patients and as combination therapy in 186 patients in the prior year, of whom 38% were diagnosed with OAG and 31% were diagnosed with normal-tension glaucoma. Mean ECP-reported effectiveness of LB (0 [very poor] to 10 [very good]) was 9.2 in patients with no prior treatment and 8.0 in patients with failed IOP-lowering drops and failed selective laser trabeculotomy and/or minimally invasive glaucoma surgery. Mean ECP-reported overall satisfaction with LB (0 [very dissatisfied] to 10 [very satisfied]) was 9.2.

CONCLUSION: LB is an effective IOP-lowering treatment in real-world practice, with good clinical outcomes and high levels of ECP satisfaction.